重庆医学2012，Vol.41Issue(22)：2265-2267,3.DOI:10.3969/j.issn.1671-8348.2012.22.014
谷红注射液联合奥拉西坦治疗血管性认知障碍的疗效观察
Efficacy of combiration therapy with Kingtag and Oxiracetam for the patients with vascular cognitive impairment
摘要
Abstract
Objective To observe the efficacy and safety of the combiration therapy with Kingtag and Oxiracetam for the patients with vascular cognitive impairment(VCI).Methods According to the score of neuropsy chological test,a total of 226 patients with vascular cognitive impairment were divided in two groups: vascular cognitive impairment no dementia(VCIND,n = 115) and vascular dementia(VaD,n = 111) ,who were randomized to receive Kingtag and Oxiracetam(intervention group) ,physiological saline and OxiracetamC control group) respectively.Before and after treatment,the Montreal Cognitive Assessment(MoCA) and activities of daily living(ADL) were assessed.Results The scores of neuropsy chological test of two groups were significantly improved after treatment for 8 weeks.There was significant difference between the two groups(P<0.05).In the VCIND group,the scores in intervention group were signficantly better than those in the control group(P<0.05).The same results were presented by intervention group among VCIND group and VaD group(P<0.05).The incidence of adverse reaction in two groups were 6.25% and 4.50% respectively.No serious adverse events occured during the experment.Conclusion The combiration therapy with Kingtag and Oxiracetam has positive effect and cause less adverse reaction for patients with vascular cognitive impairment,it s worth popularizing in clinic.关键词
谷红注射液/奥拉西坦/血管性认知障碍/疗效Key words
Kingtag/Oxiracetam/vascular cognitive impairment/efficacy引用本文复制引用
陈敏,罗欣,张玉方,王霆,李苌清..谷红注射液联合奥拉西坦治疗血管性认知障碍的疗效观察[J].重庆医学,2012,41(22):2265-2267,3.基金项目
国家十二五"重大新药创制"科技重大专项基金资助项目(2011ZX09201-101-3 （）
2011zx09401-301-4). （）
